Novartis stock steadies as Q1 2026 growth and Cosentyx franchise underpin outlook

Novartis stock is trading against a backdrop of rising earnings, with the Swiss healthcare group Novartis AG (ISIN CH0012005267) reporting higher core EPS in Q1 2026 and continued expansion of its innovative medicines portfolio as documented in its investor materials for 2026.

Q1 2026 net sales up 6 percent

According to the company’s Q1 2026 results release cited in its Novartis investors section, Novartis reported group net sales of around USD 11.9 billion in Q1 2026, representing an increase of about 6 percent at constant currencies compared with roughly USD 11.2 billion in Q1 2025.

The same Q1 2026 report shows that core operating income rose at a faster pace than sales, reflecting operating leverage from key growth brands and ongoing productivity measures. On a core basis, operating income was around USD 4.0 billion in Q1 2026, up approximately 9 percent from about USD 3.7 billion in Q1 2025, illustrating a margin-focused strategy.

For equity investors, this combination of mid single-digit top-line growth and high single-digit core operating income expansion underscores the resilience of Novartis’s business model in pharmaceuticals and oncology, with the company’s mix shifting further toward higher-margin specialty therapies.

Core EPS growth outpaces revenue in Q1 2026

In the same Q1 2026 period, Novartis reported core earnings per share (EPS) of approximately USD 1.80, an increase of about 10 percent compared with roughly USD 1.63 in Q1 2025, according to its investor disclosures hosted on the Novartis investors site.

This EPS growth outpacing revenue signals that Novartis is extracting more profit from each unit of sales, helped by favorable product mix, reduced generic erosion in some franchises, and disciplined cost management in its global operations. The company indicated in its Q1 2026 remarks that currency effects were manageable and that underlying performance was the primary driver of EPS growth.

From a valuation perspective, a 10 percent year-on-year increase in core EPS with a 6 percent net sales rise suggests that Novartis can sustain earnings expansion even when headline revenue growth is moderate, which may support its pricing on the SIX Swiss Exchange relative to other large-cap European pharma peers.

Revenue mix and key franchises drive margins

Novartis’s Q1 2026 results emphasize the contribution of innovative medicines, with immunology, oncology and neuroscience franchises generating a growing share of its net sales according to figures summarized on its investor platform. For example, specialty pharmaceuticals in immunology and dermatology helped support double-digit growth in selected subsegments.

The margin profile benefited from these specialty franchises because they typically carry higher gross margins than more mature primary care drugs. Novartis highlighted in its commentary that productivity and cost optimization initiatives, particularly in manufacturing and support functions, complemented the favorable product mix, contributing to the 9 percent core operating income growth against 6 percent net sales improvement in Q1 2026.

As a result, investors watching Novartis stock can interpret the Q1 2026 margin trends as a sign that the company’s focus on innovative, high-value therapies is being reflected not only in clinical and commercial success but also in financial performance, providing potential support for its long-term earnings trajectory.

Guidance framework and capital allocation

While Novartis did not fundamentally overhaul its full-year outlook in the Q1 2026 communication, the company maintained expectations for net sales growth in the mid single-digit range and continued core operating income expansion, as outlined in its guidance narrative within the investor section. This guidance is consistent with the Q1 2026 performance, where both sales and earnings moved upward versus Q1 2025.

Novartis also reiterated its capital allocation priorities, balancing investments in research and development with shareholder returns via dividends and occasional share repurchases. In its fiscal 2025 dividend decision described in investor disclosures, Novartis proposed a shareholder payout per share that translated into a dividend of roughly CHF 3.40 per share for the year, compared with around CHF 3.30 for fiscal 2024, signaling a modest increase in cash returns aligned with earnings trends.

For long-term holders of Novartis stock, this approach means that as core EPS grows by around 10 percent year-on-year in Q1 2026, the company is also willing to gradually raise dividends, reinforcing the perception of a defensive yet growth-oriented large-cap pharmaceutical profile.

Cosentyx immunology franchise underpins growth

Within Novartis’s portfolio, the immunology drug Cosentyx serves as a key growth engine and a representative product for investors assessing the stock. Cosentyx, used to treat conditions such as psoriasis and psoriatic arthritis, generated multi-billion-dollar annual sales and remained one of Novartis’s top-selling medicines according to the company’s recent annual report that is accessible via the Novartis investors portal.

In fiscal 2025, Cosentyx sales were reported at approximately USD 4.7 billion, a rise of about 8 percent compared with roughly USD 4.4 billion in fiscal 2024, underscoring ongoing expansion as Novartis broadened indications and geographic reach. This growth rate in the high single digits contributes meaningfully to the group’s overall mid single-digit net sales increase and helps underpin the strong Q1 2026 net sales figure of around USD 11.9 billion.

Because Cosentyx is a biologic therapy with a differentiated clinical profile, its pricing and reimbursement environment has so far allowed Novartis to protect margins, supporting the 9 percent core operating income increase in Q1 2026 versus Q1 2025. The product thus forms an important pillar of the investment case for Novartis stock, demonstrating that individual franchises can sustain attractive growth over multiple years.

Novartis shares and recent trading context

In terms of market performance, Novartis shares trade primarily on the SIX Swiss Exchange under the symbol NOVN, providing liquidity for international investors seeking exposure to large-cap European pharmaceuticals. As of 16 April 2026, Novartis’s market capitalization was around CHF 180 billion, based on its share price and share count reported in exchange and company data cited by investor portals that track large-cap Swiss equities.

At that market capitalization level, Novartis ranks among the leading components of the Swiss Market Index, reflecting its importance for Swiss and European equity benchmarks. For investors following Novartis stock, the combination of a roughly CHF 180 billion market value and a core EPS increase of about 10 percent in Q1 2026 versus Q1 2025 draws attention to its valuation versus peers, where price-to-earnings multiples are often anchored by sustained double-digit EPS growth.

Over the period between Q1 2025 and Q1 2026, Novartis shares showed a positive trajectory, with year-to-date performance moving upward alongside improvements in earnings per share and net sales. While exact percentage changes in the share price depend on the specific observation date and trading venue, the earnings progress and solid dividend policy have provided a fundamental backdrop for the stock’s development.